{"links":{"html":"https://www.erudio.com/reports/destination-2-nct06638541","json":"https://www.erudio.com/reports/destination-2-nct06638541.json","markdown":"https://www.erudio.com/reports/destination-2-nct06638541.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"destination-2-06638541"}},"request":"https://www.erudio.com/contact?report=destination-2-06638541"},"offer":{"cited_commentary_sources":16,"verified_hcp_statements":172,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":20,"optional":true,"price_per_verified_person_usd":15,"price_usd":300,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"destination-2-nct06638541"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=destination-2-06638541","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/destination-2-nct06638541","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T07:24:29.370929Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":0},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Acute GU toxicity"},{"claim_count":15,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":9,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":39,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":11,"title":"The comparison"},{"claim_count":26,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":8,"title":"Safety and tolerability"},{"claim_count":19,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":26,"coverage":"discussed","id":"A1","source_count":5,"title":"Imaging validation, contour consistency and response-guided adaptation"},{"claim_count":34,"coverage":"discussed","id":"A2","source_count":3,"title":"Urethral and rectal protection, spacer use and planning exceptions"},{"claim_count":21,"coverage":"discussed","id":"A3","source_count":2,"title":"Platform access, workforce, research funding and reimbursement"},{"claim_count":34,"coverage":"discussed","id":"A4","source_count":8,"title":"Patient priorities, routine-care alternatives and the boundary of research"}],"counts":{"cited_sources":17,"claims_by_expression_type":{"comparison":9,"experience":34,"interpretation":28,"opinion":51,"primary_context":8,"question":12,"restatement":14,"uncertainty":11,"unspecified":5},"claims_by_kind":{"protocol_statement":7,"publication_statement":21,"source_observation":144},"clinician_statements":56,"evidence_units":148,"findings":12,"people_cited":25,"people_identity_verified":20,"people_total":27,"screened_sources":20,"verified_claims":172},"findings_index":[{"id":"F1","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":3},"has_counterview":true,"limitations":2,"links":{"context":1,"support":8},"ma_question":true,"named_voices":5,"passages":7,"sources":4,"sources_by_kind":{"commentary":2,"media":1,"publication":1}},"title":"Support for de-escalation does not settle whether the two-fraction dose is sufficient"},{"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":7},"has_counterview":true,"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":3,"passages":5,"sources":3,"sources_by_kind":{"commentary":2,"publication":1}},"title":"The margin controversy is target-specific and includes biological as well as geometric uncertainty"},{"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":3,"questions":1,"restated":0,"views":4},"has_counterview":true,"limitations":2,"links":{"context":1,"support":8},"ma_question":true,"named_voices":6,"passages":8,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Whether focal escalation adds benefit depends on the whole-gland dose, fractionation and evidence standard"},{"id":"F4","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":2,"questions":2,"restated":1,"views":2},"has_counterview":true,"limitations":2,"links":{"context":0,"support":8},"ma_question":true,"named_voices":4,"passages":8,"sources":3,"sources_by_kind":{"commentary":2,"publication":1}},"title":"Selection includes surveillance and the option of a longer course, not just choosing a boost"},{"id":"F5","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":2,"questions":1,"restated":0,"views":7},"has_counterview":true,"limitations":2,"links":{"context":0,"support":10},"ma_question":false,"named_voices":4,"passages":9,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"MRI-enabled targeting is attractive, but lesion definition and response adaptation remain uncertain"},{"id":"F6","structure":{"claims":12,"claims_by_group":{"comparisons":2,"experience":5,"questions":2,"restated":0,"views":3},"has_counterview":true,"limitations":2,"links":{"context":1,"support":13},"ma_question":false,"named_voices":6,"passages":13,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Urethral protection ranges from selective contouring to routine sparing"},{"id":"F7","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":3,"questions":1,"restated":0,"views":2},"has_counterview":true,"limitations":2,"links":{"context":0,"support":6},"ma_question":false,"named_voices":3,"passages":6,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Rectal safety concerns are expressed through concrete planning safeguards and reluctance to escalate further"},{"id":"F8","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":4,"questions":2,"restated":0,"views":4},"has_counterview":true,"limitations":2,"links":{"context":1,"support":10},"ma_question":true,"named_voices":8,"passages":10,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Spacer use remains a conditional benefit–burden discussion rather than a settled requirement"},{"id":"F9","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":3,"views":3},"has_counterview":true,"limitations":2,"links":{"context":0,"support":10},"ma_question":true,"named_voices":0,"passages":9,"sources":2,"sources_by_kind":{"media":1,"publication":1}},"title":"The early-toxicity endpoint is defended as developmental evidence, not a substitute for mature outcomes"},{"id":"F10","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":3,"questions":2,"restated":1,"views":1},"has_counterview":true,"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":1,"passages":4,"sources":2,"sources_by_kind":{"media":2}},"title":"Federated recruitment is welcomed, but operational success and statistical interpretation remain separate"},{"id":"F11","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":2,"views":7},"has_counterview":true,"limitations":2,"links":{"context":1,"support":11},"ma_question":true,"named_voices":3,"passages":9,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"publication":1}},"title":"Scalability depends on staffing, contour consistency and demonstrating the value of MR-guided adaptation"},{"id":"F12","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":3,"questions":1,"restated":2,"views":4},"has_counterview":true,"limitations":2,"links":{"context":3,"support":12},"ma_question":true,"named_voices":3,"passages":10,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"Research incentives and reimbursement can obstruct otherwise attractive treatment-shortening research"}],"medical_affairs_question":"What evidence of preserved cancer control, meaningful patient-reported benefit and reproducible delivery would justify moving this experimental approach beyond its current research setting?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Dose adequacy comes before convenience"},{"id":"section-2","level":2,"title":"PTV-free does not mean that visible lesions have no margin"},{"id":"section-3","level":2,"title":"Focal-boost benefit is not independent of the underlying regimen"},{"id":"section-4","level":2,"title":"Patient selection can favor surveillance or more fractions"},{"id":"section-5","level":2,"title":"Imaging uncertainty calls for validation, not an assumption of perfect targeting"},{"id":"section-6","level":2,"title":"Urethral sparing is debated at both the contouring and clinical-benefit levels"},{"id":"section-7","level":2,"title":"Rectal protection involves dose, motion and setup choices"},{"id":"section-8","level":2,"title":"Spacers: absolute benefit, procedural context and patient choice remain live issues"},{"id":"section-9","level":2,"title":"Early toxicity supports development, not a completed long-term evidence case"},{"id":"section-10","level":2,"title":"Federated collaboration is praised without proving treatment benefit"},{"id":"section-11","level":2,"title":"Deliverability still requires evidence of value and reliable contouring"},{"id":"section-12","level":2,"title":"Funding incentives can conflict with the longer-term value of shorter treatment"},{"id":"section-13","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, na","trial_dimensions":[{"findings":[{"id":"F9","shared_claims":3}],"id":"T1","label":"Primary endpoint: Acute GU toxicity"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F9","shared_claims":3}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F4","shared_claims":6},{"id":"F5","shared_claims":1},{"id":"F10","shared_claims":1},{"id":"F11","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":7},{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":3},{"id":"F7","shared_claims":3},{"id":"F8","shared_claims":8}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F10","shared_claims":7},{"id":"F11","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T07:24:29.370929Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T07:35:14Z","record_hash":"174790500316401380190e17c65a526d2b9eaef57d9d269305ac2ee1d3453b07","release_hash":"205028e2efca7be1eca08bf9a6717de3e4186644a7f5a48ee5d7e0a492cb2ad0","report_id":"erudio-nct06638541","run_id":"11b5282b-55d0-4cb9-bb2e-1fed8ac2f120","schema_version":"5.0","slug":"destination-2-06638541","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"DESTINATION 2 asks whether lowering radiotherapy dose to benign-appearing prostate while preserving dose to MRI-visible tumours can reduce urinary toxicity without compromising cancer control in localized prostate cancer. Commentary comes from X threads, podcasts and a YouTube video. The discussion turns on whether the two-fraction dose is adequate, how to interpret contested target-specific margin reduction, and what conditions would make MR-guided adaptation scalable.","meta_description":"20 sources screened · 172 verified statements (56 from clinicians verified by NPI or staff page) from 17 sources · 12 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-330370b85da91a2e68e3","claim-064da50f688331888970"],"id":"F1","paraphrase":"An X thread asked how to assess dose adequacy for the two-fraction prostate radiotherapy tested in DESTINATION 2.","publication_caveats":["The sources reviewed for this edition do not confirm the author's clinical role."],"source_channel":"x_thread","source_date":"2026-05-08","title":"Support for de-escalation does not settle whether the two-fraction dose is sufficient"},{"cited_claim_ids":["claim-2ad540d6737746791c97","claim-680a80221424ec99409f"],"id":"F9","paraphrase":"A podcast discussion asked how early toxicity assessments relate to clinically important longer-term outcomes.","publication_caveats":["The relevant podcast passage does not identify who was speaking.","The sources reviewed for this edition provide no DESTINATION 2 clinical outcome results."],"source_channel":"podcast","source_date":"2025-05-23","title":"The early-toxicity endpoint is defended as developmental evidence, not a substitute for mature outcomes"}]},"publication":{"approved_at":"2026-10-31T07:35:14Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":20},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on imaging to avoid missing cancer when selecting tissue for prostate radiotherapy.","Not yet captured in this edition: a remark on trial origins, hypothesis-testing role, protocol availability, ongoing recruitment and feedback shaping experimental design.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","57 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The report covers only the sources reviewed for this edition, not all clinicians or all public discussion. Some potentially relevant passages were not fully assessed, and trial-name searches may miss unnamed references or wording variants.","No DESTINATION 2 clinical outcome results are provided. The protocol publication describes planned methods and hypotheses, while interview and social-media recruitment statements describe progress at their own timepoints.","Several podcast passages cannot be assigned to a named speaker. They are not attributed to a speaker simply because the same episode includes clearly attributed statements from the speaker.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Trial involvement and presentation roles are described as the sources describe them; such involvement does not make a view independent external validation.","External-study comparisons, radiobiological calculations, economic arguments and personal experience remain attributed interpretations. They do not independently establish DESTINATION 2 efficacy, toxicity, procedural safety or cost-effectiveness.","Views about other fractionations, brachytherapy and planning safeguards are included where they inform the localized-prostate treatment decision. They are not presented as DESTINATION 2 protocol requirements."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":3,"publication":1,"registry":0,"regulatory":0,"x_thread":12,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":16,"methods":1},"count":17,"evidence_window":{"end":"2026-10-28","start":"2024-10-11"},"retrieval_snapshot":"2026-10-31T06:08:33.715770Z","timeline":[{"count":1,"week":"2024-W41"},{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W23"},{"count":2,"week":"2025-W45"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W19"},{"count":2,"week":"2026-W21"},{"count":1,"week":"2026-W36"},{"count":2,"week":"2026-W43"},{"count":2,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06638541:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06638541:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42097645","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:37fb1f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a02bb0","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a7ff31","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844402185645457567:feaeabdb-e37b-480b-9fae-616891309904","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844697765625860486:ca19dd83-81b9-4dc6-b578-d9b116eb3430","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1845761251546149303:8b56e5dd-6705-4c1a-810f-52bb017f4d33","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1931727011493581146:e2299e27-b57e-45ee-b502-79d13668e4b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986079430892995018:ae4361a8-05e1-43eb-bf54-85997e02954d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986094336463831280:08711f7c-4e82-4e8c-94c2-5df684f99f54","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986364137174184099:0688c059-2e46-4296-b442-972a6b1698dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013267425005810055:6a7f92d9-f277-4cd9-bb31-27b3c8e2fd84","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2020161048381178367:fc02acda-ab08-446b-9506-0a88f180e4f6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2035738550323617822:9fbcf53c-37d3-4dbe-81dd-bd9718b314d8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052679413519487087:bab6a7b6-9290-4a9d-8578-1c712db2ab60","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052684098557067537:a56b69fc-2026-45f1-93c0-384f2da497f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056407452090761589:706ea096-b1e7-4642-97ed-59504ef85925","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095543026546307314:04a8996f-af82-4518-b198-9bc73b829849","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112584561234223238:9438b7c4-a074-4da5-9d30-fc88758941d8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112706789972021585:28319f21-16f7-47f1-a449-362784437f42","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:dFbO8GA7iPc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":16,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":20},"count":20,"evidence_window":{"end":"2026-10-28","start":"2024-10-11"},"retrieval_snapshot":"2026-10-31T06:08:33.715770Z","timeline":[{"count":1,"week":"2024-W41"},{"count":1,"week":"2024-W42"},{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W23"},{"count":3,"week":"2025-W45"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W12"},{"count":2,"week":"2026-W19"},{"count":2,"week":"2026-W21"},{"count":1,"week":"2026-W36"},{"count":2,"week":"2026-W43"},{"count":2,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":{"reason":"Registry lists no drug interventions.","status":"not_applicable"},"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Prostate cancer","slug":"prostate-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"DESTINATION 2","aliases":["DESTINATION 2","Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions","Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions - a Randomised Trial"],"brief_title":"Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions","collaborators":["Elekta Limited","MRL Consortium"],"conditions":["Prostate Cancer"],"display_condition":"prostate cancer","display_interventions":[],"enrollment":{"count":54,"type":"ESTIMATED"},"interventions":[{"name":"Prostate radical radiotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"}],"nct_id":"NCT06638541","official_title":"Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions - a Randomised Trial","overall_status":"RECRUITING","phase":["NA"],"primary_completion_date":{"date":"2027-01-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"To describe the absolute risk and relative risk reduction of acute genitourinary (GU) toxicity (CTCAE v5) when delivering de-escalated two fraction prostate SBRT compared to uniform dose two fraction prostate stereotactic body radiotherapy (SBRT) for intermediate risk prostate cancer.","measure":"Acute GU toxicity","timeFrame":"12 weeks"}],"registered_date":{"date":"2024-10-15","type":"ACTUAL"},"registry_last_updated":"2026-03-23","registry_url":"https://clinicaltrials.gov/study/NCT06638541","short_name":"DESTINATION 2","short_name_basis":"registry_acronym","sponsor":"Royal Marsden NHS Foundation Trust","start_date":{"date":"2025-01-20","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, na","study_ids":[{"id":"CCR5984","type":"sponsor_study_id"},{"domain":"IRAS","id":"338368","type":"other"}],"study_type":"INTERVENTIONAL"}}}